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COMBATING RESISTANCE:
FEDERAL EFFORTS TO REDUCE OVERUSE,
CURB MISUSE, AND INCENTIVIZE THE
DEVELOPMENT OF ANTIBIOTIC DRUGS
Donna Hanrahan*
INTRODUCTION
Antibiotic resistance has become a significant public health concern that
stands to threaten our safety, endanger the economry, and fundamentally
change the practice of modern medicine.' According to the Centers for
Disease Control and Prevention (CDC), approximately two million people in
the United States experience an antibiotic-resistant infection each year, and
approximately 23,000 of them die as a result.2 The Infectious Diseases
Society of America (IDSA) has determined that methicillin-resistant
Staphylococcusaureus(MRSA) alone leadsto moredeaths inAmerica every
year than emphysema, Parkinson-s disease, HIV/AIDS, and homicide
combined. T he total cost of antibiotic resi stance has been esti mated to be
'twenty billion dollars in health care costs and thirty-five billion dollars
annually in lost productivity._ The severity and complexity of antibiotic
resistance compels national coordination. Understanding the grave threat of

Donna Hanrahan is an Associate in the corporate group at Lowenstein Sandier, LLP focused
on matters involving the life sciences. She holds aJ.D. from Seton Hall University School of
Law with a concentration in health law, an M.S. in bioethics from Columbia University, and
a B.A. in political science fromthe State University of New York (SU NY) at Geneseo.
1. See generally INFECTIOUS DISEASES SOC` OF AM., BAD BUGS, No DRUGS: As
ANTIBIOTIC DISCOVERY STAGNATES A PUBLIC HEALTH CRISIS BREWS (2004), https://www.id
society.org/uploadedFiIes/IDSA/Policy-andAdvocacy/Current_Topics-andIssues/Advanc
ingProduct Researchand_ Development/B ad B ugs No D rugs/Statements/As%20A nti biot
ic%20D iscovery%20Stagnates%20A%20Publ ic%20H ealth%20C ri si s%20B rews.pdf
[hereinafter BAD BUGS] (explaining the multi-faceted approach that is necessary to limit the
impact of antibiotic resistance on the public).
2. CTRS. FOR DISEASE CONTROL & PREVENTION, ANTIBIOTIC RESISTANCE THREATS IN THE
UNITED STATES 6 (2013), http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf
[hereinafter ANTIBIOTIC RESISTANCE THREATS].
3. SPELLBERG ET AL., INFECTIOUS DISEASES SOC`Y OF AM., COMBATING ANTIMICROBIAL
RESISTANCE: POLICY RECOMMENDATIONS TO SAVE LIVES 1 (2011), https://www.ncbi.nlrmnih.
gov/pmc/articles/PMC3738230/pdf/cirl53.pdf (relying on a study conducted in 2005).
4. C. Lee Ventola, The Antibiotic Resistance Crisis: Part 1: Causes and Threats, 40
PHARMACY & THERAPEUTICS 277, 283 (2015).
*
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antibiotic resistance, President Obama announced a series of federal actions
to help fight the rise of antibiotic-resistant bacteria in September 2014.s
However, these executive actions, absent binding legislation from Congress,
fail to comprehensively address antibiotic resistance.
This article addresses the public health issue of antibiotic resistance and
recommends statutory responses to reduce the overuse, curb misuse, and
incentivize the development of novel antibiotic drugs. It then suggests that
the Food and Drug Administration (FDA) impose a Risk Evaluation and
Mitigation Strategy (RE MS) restriction on novel antibiotic drug products to
conserve their use and prevent misuse. Further, this article urges Congress to
be swift and bold in implementing statutory reform to halt antibiotic
resistance by passing the Promise for Antibiotics and Therapeutics for Health
(PATH) Act to incentivize innovation in antibiotic development by creating
a new regulatory approval pathway for antibiotic drugs. Until a new
regulatory regime surrounding antibiotics is established, policymakers
should work creatively within existing statutory frameworks to curb
resistance by using the Orphan Drug Act (ODA) to spur antibiotic innovation
and the Controlled Substance Act (CSA) to promote antibiotic conservation.
Part I of this article describes the public health threat of antibiotic
resistance, explores the five main factors contributi ng to antibiotic resistance,
and concludes that an effective response to antibiotic resistance must weigh
each of these causes and devel op effective responses in kind. Part II analyzes
the role of the federal government in public health efforts, describes the
recent efforts under the Obama Administration to combat antibiotic
resistance, and analyzes recent FDA efforts to curb antibiotic resistance. It
concludes by suggesting that the FDA impose a RE MS restriction on novel
antibiotic drug products to conserve their use and prevent misuse. Part III
takes a historical look at the proposed legislation relating to antibiotic
resistance and urges Congress to act expediently to address both conservation
and innovation in the field of antibiotics by passing the PATH Act. Part IV
proposes working creatively within the existing statutory framework to
address both pharmaceutical innovation and antibiotic conservation in the
field of antibiotics through the ODA and CSA. Finally, this article concludes
by emphasizing the need for legally binding standards to reduce misuse and
incentivize the development of antibiotic drugs to curb this growing public
health concern.

5. See Lisa Monaco & John P. Holdren, New Executive Actions to Conbat Antibiotic
Resistance and Protect Public Health, THE WHrTE HOUSE: BLOG (Sept. 18, 2014, 2:33 PM),
https://www.whitehouse.gov/bl og/2014/09/18/new-executive-actions-combat-antibioticresistance-and-protect-public-health (discussing the federal actions including an Executive
Order, a national strategy for combating antibiotic-resistant bacteria, a new PCAST report,
and the launch of a twenty million dollar prize).
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I. ANTIBIOTIC RESISTANCE

Antibiotics are drugs used to treat infections caused by bacteria.6 With the
increased use of antibiotics in the practice of medicine came a sharp decline
in morbidity and mortality once associated with acute bacterial infections.7
Antibiotics allow us to quickly and accurately treat bacterial infections,
infectious diseases, foodborne illnesses, bacterial pneumonias, and other
conditions in a way that would seem miraculous a century ago to those who
practiced medicine.8 Antibiotic use also expanded the practice of medicine to
allow for a broader range of treatments.9 For instance, without antibiotics,
patients undergoing chemotherapy for cancer, or dialysis for renal failure,
would be highly susceptible to infectious complications, which may render
their treatments fatal. 10 It is difficult to imagine modern surgical procedures,
such as organ transplants, without using antibiotics to prevent potentially
fatal surgery-related infections."
Despite their medical successes, 12 antibiotics are losing their effectiveness
atan alarming rate." Since bacteria are highly adaptive microorganisms, 14 no
matter how carefully they are used, antibiotics intrinsically create
evolutionary pressure for resistance." This phenomenon has been

6. See Antibiotic Resistance and the Use of Antibiotics in Animal Agriculture: Hearing
Before the Subcomm on Health of the Comm on Energy & Commerce, 111th Cong. 33 (2010)
(statement of J oshua M. Sharfstein, Principal Deputy Comm-r, Food & Drug Admin.).
7. SeeCTRS. FOR DISEASE CONTROL & PREVENTION, Achievements in Public Health, 19001999: Control of Infectious Diseases, 48 MORBIDITY & MORTALITY WKLY. REP. 621, 621-22
(1999) (showing that after the first use of penicillin, the introduction of the Salk Vaccine, and
the Passage of the Vaccination Assistance Act, mortality was at its lowest in the late 2 0 th
century).
8. See WHITE HOUSE, NATIONAL STRATEGY FOR COMBATING ANTIBIOTIC-RESISTANT
BACTERIA 1 (2014), https://www.whitehouse.gov/sites/default/files/docs/carbnationalstrate
gy.pdf [hereinafter NATIONAL STRATEGY].

9. See Cesar A. Arias & Barbara E. Murray, Antibiotic-Resistant Bugs in the 21st
Century' A Clinical Super-Challenge, 360 NEw ENG.J. MED. 439, 439-40 (2009) (pointing
to the critical role of antibiotics in the treatments for cancer, HIV, and MRSA and the
devel opments in surgery and transplantations).
10. ANTIBIOTIC RESISTANCE THREATS, supra note 2, at 5.
11. Arias & Murray, supra note 9, at 439.
12. See Fernando Bacquero & Jesgs Blcaquez, Evolution of Antibiotic Resistance, 12
TRENDS ECOLOGY & EVOLUTION 482, 482 (1997) (noting that antibiotics represent the
'protective umbrella_ under which advancements in modern medicine, such as intensive care,
advanced surgery, chemotherapy, and organ transplantation, have been developed).
13. BAD BUGS, supra note 1, at 9.
14. See Vanessa K.S. Brice o, Superbug Me: The FDA-s Role in the Fight Against
Antibiotic Resistance, 9 N.Y.U.J. LEGIS. & PUB. POL-Y 521, 522 (2005).
15. See D. J. Austin et al., The Relationship Between the Volume of Antimicrobial
Consumption in Humn Cormunities and the Frequency of Resistance, 96 PROC. NATL
ACAD. SCI. 1152, 1152 (1999).
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exacerbated by society-s chronic misuse and overuse of antibiotics. 16
Antibiotic resistance results when bacteria mutate, or acquire new genes, in
ways that reduce or eliminate the effectiveness of antibiotics.17 T he majority

of microorganisms, which have little resistance to the antibiotic, are
destroyed, while those with the highest resistance reproduce their genetic
information." This process may occur until an entire bacterial species
becomes resistant to a certain antibiotic.19
Alexander Fleming, the father of antibiotics who developed penicillin in
1928, had the foresight to warn against the misuse of antibiotics and predicted
the dangerous phenomenon of resistance.20 In his 1945 Noble Prize
acceptance speech, he cautioned that, 'the ignorant man may easily
underdose himself and by exposing his microbes to non-lethal quantities of
the drug that make them resistant.21 Then, in 1967, U.S. Surgeon General
William H. Stewart asserted, '[t]he time has come to close the book on
infectious diseases. 22 Nearly half a century later, that book is still open
precariously wide. Moreover, the economic cost of antibiotic resistance is
steep.23 Indeed, each day, policymakers fail to act, and it becomes more
difficult and increasingly expensive to address drug resistance in the future.24
A. Factors Contributing to Antibiotic Resistance
Antibiotic-resistant organisms arise from many factors cumulatively and
cannot be reduced to a single cause. 25 Factors contributing to antibiotic

16.

See STUART B. LEVY, THE ANTIBIOTIC PARADOX: How THE MISUSE OF ANTIBIOTICS
STHEIR CURATIVE POWERS (2d ed. 2002); see also Ventola, supra note 4, at 277-283
(illustrating how a physicians- tendency to over-prescribe and patients- tendency to fail in
completing the course of treatment are two societal factors which have contributed to antibiotic
resistance).
17. NATIONAL STRATEGY, supra note 8, at4.
18. DAN J. TENNENHOUSE, 2 ATTORNEY<S MEDICAL DESKBOOK f 22:24, Westlaw
(database updated Oct. 2015).
19. See Bacquero & Blaquez, supra note 12, at 484.
20. Alexander Fleming, Penicillin, Nobel Lecture (Dec. 11, 1945) in NOBEL LECTURES
83, 93, http://www.nobelprize.org/nobel-prizes/medicinelaureates/1945/flering-lecture.pdf.
21. Id.
22. See, e.g., Ross Upshur, Ethics and Infectious Disease, 86 BULL. WORLD HEALTH ORG.
654, 654(2008), http://www.who.int/bulletin/volurmes/86/8/08-056242/en/
DESTROY

23.

See BAD

BUGS,

supra note 1, at 10.

24. Press Release, Ctrs. for Disease Control & Prevention, CDC Year in Review:
'Mission: Critical_ (Dec. 15, 2014), http://www.cdc.gov/m-edia/releases/2014/pl215-2014year-in-review.html.
25. INST. OF MED. FORUM ON EMERGING INFECTIONS, 5 Factors Contributing to the
Emergence of Resistance, in THE RESISTANCE PHENOMENON IN MICROBES AND INFECTIOUS
DISEASE VECTORS: IMPLICATIONS FOR HUMAN HEALTH AND STRATEGIES FOR CONTAINMENT:
WORKSHOP SUMMARY 130,130 (Stacey L. Knobleretal. eds., The National Academies Press

2003), https://www.ncbi.nim.nih.gov/books/NBK97126.

https://lawecommons.luc.edu/annals/vol26/iss1/5

4

Hanrahan: COMBATING RESISTANCE: FEDERAL EFFORTS TO REDUCE OVERUSE, CURB MIS

2017

Combating Resistance

71

resistance include: (1) overuse through over-prescription, (2) misuse through
failure to complete course of treatment, (3) failure to contain antibioticresistant infections in healthcare settings, (4) factory farming and
subtherapeutic use in meat products, and (5) barriers to pharmaceutical
innovation given the current patent system and the price/volume business
model on which the industry currently operates. 26 Each factor must be
considered to develop an effective response to antibiotic resistance.
1. Overuse Through Over-P rescri pti on
Antibiotic resistance is perpetuated by the excessive use of antibiotics in
humans. 27 The CDC estimates that approximately fifty percent of all the
antibiotics prescribed for patients in the United States are unnecessary or not
optimally prescribed. 28 In addition, many physicians erroneously recommend
antibiotics for viral infections. 29 This is due in part to the appearance of a
tangible medical intervention, as com-pared to the indirect relief of symptoms
or a mere 'wait it out_ approach.30 Many patients insist on receiving novel
antibiotics when other approaches may be equally, or in some cases more,
efficient.31 This phenomenon demonstrates that physicians may be
'acquiescing to their patients- demands in order to deliver a positive
treatment outcome and retain the patients-business. _32 Physicians must keep
these concerns about overuse in mind and prescribe antibiotics prudently to
preserve the limited amount of effective medications.33
Antibiotic cycling is one antibiotic utilization strategy that may slow the
development of antibiotic resistance. Antibiotic cycling occurs when
different classes of antibiotics are deliberately alternated and rotated in a
given population for a period of time. 4 As early as the 1980s, the
Minneapolis Veterans- Affairs Medical Center-s cycling efforts of the
antibiotics gentamicin, tobramrycin, and amikacin effectively reduced
gentanicin resistance.35 However, cycling policies are difficult to enforce

26. See V entola, supra note 4, at 277-283.
27. See ANTIBIOTIC RESISTANCE THREATS, supra note 2, at 11.
28. Id.
29. See Cory Fox, Resisting Antibiotic Resistance: Legal Strategies to Maintain Man-s
Dorninion Over Microbes, 12 Hous.J. HEALTH L. & POL-Y 35,42(2011).
30. Richard S. Saver, In Tepid Defense of Population Health: Physicians and Antibiotic
Resistance, 34AM.J. L.& MED.431, 471 (2008).
31. Fox, supra note 29, at 41 -42.
32. Id. at 42.
33. See Saver, supra note 30, at 435.
34. See Erwin M. Brown & Dilip Nathwani, Antibiotic Cycling or Rotation: A Systerntic
ReviewoftheEvidenceofEfficacy, 55J.ANTIMICROBIAL CHEMOTHERERAPY 6, 6(2005).
35. Joseph F. John, Jr., Editorial, Antibiotic Cycling: Is It Ready For Prime Tirre?,
21.1 INFECTION CONTROL & HosP. EPIDEMIOLOGY 9, 9-10(2000) (explaining thatgentamicin,
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and efforts have been sporadic at best. 6 Many factors can affect the outcome
of cycling programs, such as which antibiotics are cycled, the order in which
they are cycled, and the length of each cycle. 7 Healthcare institutions must
carefully adjust these factors and optimize antibiotic utilization strategies for
their particularized setting to succeed in reducing resistance.
2. Misuse Through Failure to Complete Course of Treatment
Many patients unknowingly contribute to antibiotic resistance by failing
to complete their entire course of treatment, thus failing to eradicate the
infection from their bodies. 8 Patients often stop taking their antibiotics when
their symptoms improve because they do not recognize that the drug has not
yet effectively eliminated the underlying bacteria." This causes eradication
of bacteria with the weakest resistance, but high-resistance bacteria will
remain and reproduce.40 Many patients remain unaware that such behavior
can help fuel antibiotic resistance problems. 41
To prevent misuse and curb antibiotic resistance, patients must take greater
responsibility toward their treatments. Moreover, physicians must find
innovative ways to sufficiently educate their patients and support
adherence.42 Physicians must take time to emphasize the need to adhere to
dosage amounts and length of treatment in order to maximize the benefit to
the patient and minimize resistance problems.43 Methods to increase
medication adherence must also be developed. These adherence methods
could range from high tech mobile applications and 'smart_ pill bottles to
simple and cheap methods, such as adding a milestone to a treatment (i.e.
advising patients to complete ten white pills before completing five blue pills
of the same drug) to increase adherence. 4 These measures will help patients

tobrarmycin, and amikacin fall under the antibiotic category of arrinoglycosides, used in the
treatment of gram-negative bacterial infections); Marie-Paule Mingeot-Leclercq et al.,
Aminoglycosides: Activity and Resistance, 43 ANTIMICROBIAL AGENTS & CHEMOTHERAPY
727, 727 (1999).
36. See Erwin M. Brown & Dilip Nathwani, Antibiotic Cycling or Rotation: A Systemtic
Review of the Evidence of Efficacy, 55 J. ANTIMICROBIAL CHEMOTHERERAPY 6, 6-9 (2005)
(discussing the methodological flaws and lack of standardization that render the results of
studies evaluating the efficacy of antibiotic cycling to be unreliable, as many issues relating to
cycling remain unaddressed).
37. Id. at 8-9.
38. See Fox, supra note 29, at 41.
39. Bacquero & Blcaquez, supra note 12, at485.
40. TENNENHOUSE, supra note 18.
41. Id.
42. See Saver, supra note 30, at 472.
43. See id. at 450 (explaining that physician management of antibiotics must extend to
beyond prescribing and include monitoring and counseling use).
44. E. Patchen Dellinger et al., Quality Standard for Antimicrobial Prophylaxis in

https://lawecommons.luc.edu/annals/vol26/iss1/5
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complete thei r treatment and maximize the effect of antibiotics.
3. Failure to Contain A ntibiotic-Resistant Infections in Healthcare Settings
Hospital-acquired infections that spread resistant bacterial strains among
inpatients and healthcare facility staff far exceed what we should be willing
to tolerate.4 5 Institution-acquired antibiotic infections can be caused by
breaches in safety and infection control protocol in healthcare settings,
including hospitals and nursing homes.46 Patients with antibiotic-resistant
infections and non-infected susceptible patients are often kept in close
proximity, even though physical separation of patients is preferred. 47
Deviations from protocol, such as hand washi ng or sterilization of equipment,
can also have devastating effects.4 For example, in February 2015, the
UC LA H ealth System linked the deaths of two patients to a superbug known
as carbapenem- resistant enterobacteriaceae (CRE) as a result from
unsterilized endoscopy equipment.49 CRE is resistant to virtually all known
antibiotics and kills up to fifty percent of people infected.s0 Some patients
who acquired these deadly CRE bacteria were fairly healthy and receiving
routine endoscopies.1 T his is a sad example of the health system failures that
result in patients leaving sicker than they had arrived, or worse yet, not
leaving at all.
Seventy percent of hospital-acquired infections are resistant to at least one
antibiotic. 5 2 Moreover, the FDA has estimated that approximately 150,000
hospital-acquired infections involve resistant strains of bacteria annually,
resulting in an extra $375 million in hospital charges per year.13 The
Surgical Procedures, 18 CLINICAL INFECTIOUS DISEASES 422, 422 (1994) (emphasizing the
need to deternine optimal timing, dose and duration for drug therapy).
45. See Saver, supra note 30, at 432 (explaining that drug-resistant hospital-acquired
infections cause more deaths per year than 'HIV-AIDS, Parkinson-s, emphysema, or
homicide).
46. See generally AMY S. COLLINS, Chapter 41 Preventing Health Care-Associated
Infections in PATIENT SAFETY AND QUALITY: AN EVIDENCE-BASED HANDBOOK FOR NURSES
(2008), https://www.ncbi.ninih.gov/books/NBK2683/ (discussing systematic antibiotic
controls in health care settings and how they impact the rate of hospital acquired infections).
47. Seegenerally Ruth M. Kleinpell etal., Chapter 42 Targeting Health Care-Associated

Infections: Evidence-Based Strategies in PATIENT SAFETY AND QUALITY: AN EVIDENCE-BASED
HANDBOOK FOR NURSES: VOL. 2 2-577 (2008), https://www.ncbi.nlmnih.gov/books/NBK2
632/pdf/B ookshelf_ N B K 2632. pdf.
48. Id. at 2-577-78.
49. Bill Briggs, UCLA :Superbug- Patient to Sue Maker of Suspect Endocopes, NBC
NEWS (Feb. 20, 2015), http://www.nbcnews.com/health/health-news/ucla-superbug-patientsue- maker-suspect-endocopes-l awyer-n309891.
50. Id.
51. Id.
52. BAD BUGS supra note 1, at3.
53. Saver, supra note 30, at 441.
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pervasiveness of antibiotic-resistant infections can transform hospitals into
health threats due to the increased presence of MR SA and other common, yet
dangerous, infections.
Rather than blame, there needs to be greater accountability for healthcare
safety practices at the systemic level. T he medical communi ty should address
how to better improve adherence to simple, yet effective approaches to
safety, including hand-washing, checklists, and personal protective
equipment monitoring to avoid the pitfalls that place healthcare workers at
risk when treating patients with infectious diseases. Then, we will be able to
comfortably rely on established health and safety protections.
4. Factory Farming & Meat Products
Antibiotics have been administered in livestock for nontherapeutic
purposes, namely to promote the growth of livestock for human consumption,
without any investigation into potential consequences.ss Starting in the late
1940s, livestock have been subjected to sub-therapeutic levels of antibiotics
simply so that they can grow larger, known as the 'antibiotic growth effect. _s6
With the increase in 'factory farms_ in the early 2000s, this issue was
exacerbated, as it is nearly impossible to prevent the spread of disease among
animals kept in such close quarters.5 7 Food-related Salmonella and E. coli
outbreaks suggest that these diseases may be passed to humans when the
animals are slaughtered and eaten." In addition, resistant bacteria can spread
from food animals to humans through manure and other environmental
factors. 9 For these reasons, subtherapeutic use of antibiotics in livestock is a
primary factor contributing to antibiotic resistance.'
5. Pharmaceutical Innovation & Patent Law
The research and development (R&D) of new antibiotics has sharply
54. See Lauren Orrico, Squashing the Superbugs: A Proposed Multifaceted Approach to
Conbatting Antibiotic-Resistant Bacteria, 27J. OF L. & HEALTH 259, 269(2014).
55. SeeJay P. Grahamet al., Growth Promoting Antibiotics in Food Animal Production:
An Econoic Analysis, 122 PUB. HEALTH REPs. 79, 80 (2007) (explaining the health concerns
and lack of testing for animal antibiotics).
56. Id.
57. See Factory Farm Nation: How Arerica Turned its Livestock Farms into Factories,
FOOD & WATER WATCH 2(Nov. 2010), http://www.factoryfarmmap.org/wp-content/uploads/
2010/11/FactoryFarmNation-web.pdf ('Crowded, unsanitary conditions leave animals
susceptible to disease, drive the overuse of antibiotics and hormone treatments, and can
contribute to foodborne illnesses. _) [hereinafter Factory Farm Nation].
58. See Karen Florini & Rebecca J. Goldburg, Playing Chicken With Antibiotics, 22
ENVTL. F. 22, 23-24 (2005) (discussing the rapid spread of disease and the resistance of
antibiotics).
59. Factory Farm Nation, supra note 57, at 2.
60. Id.
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declined in recent decades. 6 1 Thus, we are left without a pipeline of novel
antibiotics to replace those gradually lost to antibiotic resistance.62 Large
pharmaceutical companies, once trail blazers in the field of antibiotic R& D,
have since shifted their focus to more profitable research activities.' For
instance, United States antibiotic sales peaked in 2005 and have subsequently
declined compared to other prescription drugs.' Relatedly, the total number
of new antibacterial agents approved by the FDA has declined consistently
overthe Iasttwenty-fiveyears. 6s For example, the FDA approved sixteen new
systemic antibacterial agents in 1983-1987,66 yet approved only two new
systemic antibacterial agents from 2008-2012.67
R&D is often associated with time-consuning and expensive regulatory
challenges associated with conducting the clinical trials needed for new drug
approval, and research in antibiotic drug development is no exception.' One
of the most significant reasons for the failure in antibiotic drug development
is the low economic return that makes the devel opment of novel antibiotics
an unattractive investment. 9 Si nce the pharmaceutical industry operates on a
price/volume model, it demands that R&D funds be allocated where return
on investment (ROI) is greatest thus incentivizing investment in products
that will sell at the greatest volume or at the highest price.70
Unfortunately, the ROI for antibiotics is low. 71 First, lost-cost generic

61. The decline in R&D investment began over ten years ago. In 1990, half of the large
pharmaceutical companies in the United States and Japan either halted or decreased their
antibiotic discovery efforts. This trend continued in 2000 when spun off its anti-infective
discovery division. Furthermore, Bristol-Myers Squibb Company Abbott Laboratories, Eli
Lilly and Company, and Wyeth all halted or substantially reduced their anti-infective
discovery efforts in 2002. More companies continueto indicate a decline in their R& D efforts.
BAD BUGS, supra note 1, at 14.
62. Brad Spell berg et al., The E pideic ofAntibiotic-ResistantInfections: A Call toAction
for the Medical Cormunity from the Infectious Diseases Society of America, 46 OX FORD J.
CLINICAL INFECTIOUs DISEASES

155, 155 (2008), www.idsociety.org/workarea/download

asset.aspx?id=9048.

63.

See BAD

BUGS,

supra note 1, at3.

64.

Kevin Outterson et al., Repairing the Broken Market for Antibiotic Innovation, 34
HEALTH AFF. 277, 278-79 (2015), http://content.healthaffairs.org/content/34/2/277.abstract.
65. Spell berg et al., supra note 62, at 158.
66. BAD BUGS, supra note 1, at 15.
67. Mari Sevebrov, U.S. Goes On The Offensive To Keep Superbugs In Check,
BIoWORLD,
http://www.bioworld.com/content/us-goes-offensive-keep-superbugs-check-0
(last visited Nov. 14, 2016).
68. See Cindy R. Friedman & Cynthia G. Whitney, It-s Time for a Change in Practice:

Reducing Antibiotic Use can Alter Antibiotic Resistance, 197 J. INFECTIOUs

DISEASES

1082,

1082(2008).
69. Outterson et al., supra note 64, at 279.
70. See id. at 278.
71. Id. at 279.
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antibiotics are available in the majority of clinical circumstances. 72 In fact,
the antibiotics drugs are so inexpensive that despite accounting for 6.4
percent of all U.S. prescriptions in 2013 by volume, they conposed only 2.6
percent of prescriptions by value.' Second, market uptake is limited, due in
part to public health efforts to curb unnecessary antibiotic prescriptions.74 In
order to prevent antibiotic resistance, the use of novel antibiotics are
systemically discouraged, except for in the most extreme cases.7 Thus,
profitability is limited. 6 Ironically, antibiotics are sometimes seen as
'victims of their own success. _ While they are often more effective than
their alternatives, their use must be limited to maintain their efficacy and
yield an individual and public health benefit7' With the rise of antibiotic
education and stewardship programs, the market for new antibiotics will
continue to be appropriately restricted. Third, the lower rate of ROI on
antibiotics, as compared to other products, is due in part to their short-term
therapeutic use. Not only are antibiotic treatments temporary by nature, they
completely cure the target disease as well.'
Fourth, the value of antibiotics cannot be appropriately quantified, as the
value of the drugs- benefit extends beyond patient use' the broader
population also stands to benefit from the targeted use of new antibiotics by
not developing costly, and possibly deadly, antibiotic-resistant infections."
This public health value is not captured in willingness to pay and thus it is
not reflected in pricing models.82 Aaron S. Kesselheim, an instructor in
medicine
in the
Division
of
Pharmacoepideniology
and
Pharmacoeconomics, Department of Medicine, at Brigham and Women-s
Hospital and Harvard Medical School, and Kevin Outterson, an associate
professor of law at the Boston University School of Law, both experts in
antibiotic resistance, contend that the 'current legal structures and market
incentives unwittingly accelerate resistance in several ways, all rooted in the
mismatch between private and social value. _ 83They argue that the substantial

Id. at 278.
Id.
Id.
See E. Power, Impact of Antibiotic Restrictions: The Pharaceutical Perspective, 12
CLINICAL MICROBIOLOGY & INFECTION 25, 29 (2006).
76. Id.
77. Spell berg et al., supra note 62, at 158.
78. Id.
79. Outterson et al., supra note 64, at 278.
80. Spell berg et al., supra note 62, at 158.
81. Outterson et al., supra note 64, at 278.
82. Id.
83. Aaron S. Kesselheim & Kevin Outterson, Improving Antibiotic Markets for Long
Term Sustainability, 11 YALEJ. HEALTH POL-Y, L. & ETHICS 101, 105(2011).
72.
73.
74.
75.
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divide between the private and social value of antibiotics has led to a
troubling supply and demand incentives and an increase in antibioticresistant infections. Further, they maintain that 'the patent system helps spur
innovation of new drugs, but pending patent expiration may lead antibiotic
manufacturers to waste their products by promoting drug use for a broad
array of ninor clinical conditions, rather than trying to assure that their
products are limited to the most urgent cases._" Thus, the devel opment of
antibiotic therapies is not profitable in a patent-centered market which
requires pharmaceutical companies to capitalize on sales during the drug-s
patented years, as antibiotics are only effective if their use is conserved.
Large publicly traded pharmaceutical companies, despite having
beneficent mission statements and legitimate aims of developing novel
medical treatments for the public benefit, are also beholden to their
shareholders.85 The pharmaceuti cal industry could reasonably determine that
it is not economically viable to risk expending capital on antibiotic R&D
when other drug categories have higher earning potential." Thus, itwould be
reasonable for a publicly traded company to reject antibiotics R& D in pursuit
of a new 'Blockbuster_ drug for a therapeutic area with a wider patient
population.' Indeed, as of 2008, only five of the fifty largest pharmaceutical
companies are home to active antibiotic-development programs. Bearing
this in mind, it comes as no surprise that companies are dissuaded from
investing in the development of antibiotic drugs.
Even when drug companies invest in R& D for antibiotics, they are drawn
only to the largest markets.' Of the six most dangerous groups of
microorganisms demonstrating increasing rates of antibiotic resistance, only
M RSA has seen some advancement due to its clinical notoriety and increased
market incentives.' On the other hand, the remaining five priority pathogens
with smaller potential markets have far fewer new agents in the pipeline.91
Comprehensive and coordinated planning among various sectors of the
healthcare industry is necessary to overcome this tension between
pharmaceutical innovation and antibiotic conservation.
Antibiotic resistance arises from many factors cumulatively, and thus

84. Id.
85. See Spellberg et al., supra note 62, at 161 (explaining that 'corporate directors have a
fiduciary responsibility to invest their R&D dollars in a manner that maximizes the likelihood
of return on investment ).
86. Id.
87. See id.
88. Theresa Braine, Race Against Tirre to Develop New Antibiotics, 89 BULL. WORLD
HEALTH ORG. 88, 88-89(2011), http://www.who.int/bulleti n/vol umes/89/2/11-030211 /en/.
89. Kesselheim& Outterson, supra note83, at 120.
90. Id. at 117-18.
91. Id.
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requires a multifaceted response. An effective response to antibiotic
resistance must give weighted consideration to each of these causes and
develop effective strategies in kind. Having explored the economic and social
cost of antibiotic resistance and the factors contributing the phenomenon,
Part II will now explore the role of the federal government in public health,
analyze recent efforts under the Obama Administration, and propose that the
FDA implement a REMS restriction as a solution to combat antibiotic
resistance.
II. FEDERAL EFFORTS TO COMBAT ANTIBIOTIC RESISTANCE

Antibiotic resistance is an imminent public health concern that requires
national coordination, and is therefore ripe for federal action. Understanding
the severity of the public health threat, President Obama launched an
executive campaign in 2014 to reduce the chronic overuse of antibiotics, as
well as to incentivize the development of novel antibiotic drugs. 92 Foremost,
Executive Order 13676, titled 'Combating Antibiotic-Resistant Bacteria,
calls for (1) improved monitoring of resistant infections; (2) more stringent
regulations governing antibiotic use; (3) more robust research to innovate
treatments; and (4) greater international cooperation to address the issue of
antibiotic-resistant bacteria.' The Executive Order also demands that the
Task Force submit a five year National Action Plan ('Action Plan),
including goals, milestones, ti mel i nes, and metrics for measuring progress."
In addition, as a part of these executive efforts to combat antibiotic
resistance, President Obama announced that the National Institutes of
Health (NIH) and Biomedical Advanced Research and Development
Authority (BARDA) launched a $20 million prize to 'facilitate the
development of a rapid diagnostic test to be used by health care providers to
identify highly resistant bacterial infections at the point of patient care. _
President Obama also requested that the President-s Council of Advisors on
Science and Technology (PCAST) create a National Report on Combating
Antibiotic Resistance.9 6 Further, President Obama charged the National
Security Council (NSC) and the Office of Science and Technology Policy
(OSTP) to create a National Strategy for Combating Antibiotic Resistance.
These reports have been completed, and they establish broad goals to slow
the emergence of resistant bacteria and prevent the spread of resistant
92. See generally Combating Antibiotic-Resistant Bacteria, 184 Fed. Reg. 56, 931 (Sept.
23, 2014).
93. Id.
94. Id.
95. Monaco & Holdren, supra note 5.
96. NATIONAL STRATEGY, supra note 8, at 1.
97. Combating Antibiotic-Resistant Bacteria, 184 Fed. Reg. 56, 931.
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infections, strengthen surveillance, accelerate R&D for new antibiotics, and
improve international collaboration.98
While these calls to action are certainly welcomed, these measures remain
little more than 'feel good_ actions without statutory and regulatory teeth.
Taking President Obama-s lead, the FDA and Congress should implement
statutory reform to halt antibiotic resistance as a mounting public health
concern, while simultaneously preserving incentives to continue developing
new antibiotics.
A. The Role of the FDA
The FDA recognized antibiotic resistance as a health concern as far back
as 1977, but has yet to effectively limit the use of antibiotics for human
disease prevention and growth promotion in food animals.' Despite its
criticisms for inaction, the FDA has taken some steps towards regulating
antibiotics to prevent overuse and abuse in livestock. 100 The FDA issued two
G ui dances for Industry (G FI #209 and #213) that request voluntarily phasing
out antibiotics in livestock for production purposes and advise that licensed
veterinarians should oversee uses of antibiotic drugs in livestock.101 These
GFIs also advise that animal drug companies should change their labels on
drugs to withdraw any claims that such drugs can be used for growth
promotion. 102
The FDA has also taken steps towards regulating antibiotics to prevent
overuse and abuse in humans through labeling requirements.10 3 As of 2003,
the FDA requires that antibiotic labels display information about the risks of
antibiotic resistance by reminding physicians that the drug should be used
only to treat infections proven or highly suspected to be bacterial in order to

98. NATIONAL STRATEGY, supra note 8, at 1-2.
99. Nat. Res. Def. Council, Inc. v. U.S. FDA, 884 F. Supp. 2d 127, 134-36 (S.D.N.Y.
2012).
100. See U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY #209, THEJUDICIOUS USE
OF MEDICALLY IMPORTANT ANTIMICROBIAL DRUGS IN FOOD-PRODUCING ANIMALS 9 (2012),
http://www.fda.gov/downloads/animalveterinary/guidancecomplianceenforcement/

guidanceforindustry/ ucm216936.pdf [hereinafter

GUIDANCE FOR INDUSTRY #209]; see also
FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY #213, NEW ANIMAL DRUGS AND NEW
ANIMAL DRUG COMBINATION PRODUCTS ADMINISTERED IN OR ON MEDICATED FEED OR
DRINKING WATER OF FOOD-PRODUCING ANIMALS: RECOMMENDATIONS FOR DRUG SPONSORS
FOR VOLUNTARILY ALIGNING PRODUCT USE CONDITIONS WITH GFI #209 8 (2013),

U.S.

http://www.fda.gov/downloads/AnimalV eterinary/G uidanceCom-plianceE nforcerent/G uidan

ceforIndustry/UCM299624.pdf [hereinafter GUIDANCE

FOR INDUSTRY

101. GUIDANCE FOR INDUSTRY #209, supra note 100, at9;
supra note 100, at 8.
102. GUIDANCE FOR INDUSTRY #209, supra note 100, at9;
supra note 100, at 8.
103. S aver, supra note 30, at 466.
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combat antibiotic resistance.1" The drug label must also advise physicians to
use appropriate screening tests to prescribe the proper antibiotic. 10s Lastly,
the label must remind physicians to counsel their patients to follow their
course of treatment from start to finish to avoid resistance problems.106
However, these labeling requirements are often ignored by prescribing
physicians and have had little influence on prescribing practices. 10 7
B. RE MS for Antibiotics
The FDA has the capacity to regulate the use of antibiotics in humans and
animals through its authority to establish RE MS restrictions.108 RE MS was
created as a part of the Food and Drug Administration Amendments Act of
2007 (FDAAA). 10 REMS restrictions allow the FDA to limit the use of a
particular drug to instances where its benefits are likely to outweigh its risks
by mandating additional post-market requirements.110 The FDA may use
RE MS restrictionsto limit accessto new or existing drugs, block the approval
of new drugs, or withdraw the approval of existing drugs." The FDA can
impose a RE MS restri cti on in many forms, hi ngi ng on el ements to assure safe
use, including: (1) allowing a restricted drug to be prescribed only by certain
practitioners with special qualifications; 1 12 (2) requiring certification for
entities that dispense a restricted drug;" (3) requiring that drugs be
administered only in specific healthcare settings, rather than at home; 1 14 (4)
requiring that patients comply with certain conditions of use;" (5) requiring
patients to be monitored to detect adverse events; 11 6 and (6) requiring patients
taking a restricted drug to enroll in a registry to survei I outcomes. 117 The FDA
can impose a RE MS restriction at any time in a drug-s lifecycle.118 REMS
restrictions have also been effective in practice, as in 2012,119 when the F DA
104. 21 C.F.R. f 201.24 (2008).
105. S aver, supra note 30, at 466.
106. Id.
107. Id. at 468.
108. BarbaraJ. Evans, Seven Pillars of a New Evidentiary Paradigm The Food, Drug,
and Cosmetic Act Enters the GenorTic Era, 85 NOTRE DAME L. REV. 419, 511-12 (2010).
109. Id.
110. 21 U.S.C. f 355-1(a)(2)(A) (2008).
111. Fox, supra note 29, at 58.
112. 21 U.S.C. f 355-1(f)(3)(A).
113. 21 U.S.C. f 355-1(f)(3)(B).
114. 21 U.S.C. f 355-1(f)(3)(C).
115. 21 U.S.C. f 355-1(f)(3)(D).
116. 21 U.S.C. f 355-1(f)(3)(E).
117. 21 U.S.C. f 355-1(f)(3)(F).
118. Evans, supra note 109, at 512.
119. See Risk Evaluation and Mitigation Strategy (RE MS) for Extended-Release and
Long-Acting Opioids, U.S. FOOD & DRUG ADMIN., www.fda.gov/Drugs/DrugSafety/Inforrmt
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used RE MS to restrict the distribution of over twenty narcotics, most closely
associated to drug-related deaths in the United States. 120 Further, the FDA
may impose civil monetary penalties for violations of the REMS provisions,
in addition to the deeming the drug misbranded. 12 1
While the FDA has yet to use REMS restrictions for any antibiotic
products, it is certainly within their purview to do so. 12 2 A novel antibiotic,
whose efficacy and longevity depends on its linited use, warrants a RE MS
restriction to protect the public health. 123 In the context of antibiotics, RE MS
restrictions would aim to limit the prescription of a certain antibiotic drug to
instances where they are absolutely clinically necessary.124 For example, the
FDA could require that patients undergo testing to confirm the type of
bacterial infection before being prescribed a REMS-restricted antibiotic or
place limits on physicians- prescribing abilities. 125 Imposing a REMS
restriction could therefore effectively reduce the rate of antibiotic resistance
and prolong the effective lifespan of the drug. 12 6
Some fear that RE MS restrictions to conserve anti bi oti cs in the clinical
context may threaten physician autonomry by interfering with the practice of
medicine. 127 Congress intended the Federal Food, Drug, and Cosmetic Act
('FD&C Act_ to regulate the safety of drugs, but did not allow for it to
inhibit a physician-s ability to prescribe drugs, once they have been
approved. 12 8 REMS restrictions run the risk of a having a chilling effect on
antibiotic prescriptionsto patients who actually need therr thereby adversely
affecting patient outcomes. 129 However, in clinical practice, a REMS
restriction is not likely to limit patient access. Rather, the system merely adds
a system of checks on the prescribing physician to affirm that the drug is

&

ionbyDrugClass/ucml 63647.htm (lastvisited Nov. 14, 2016) (providing an example of RE MS
restriction usage in 2012).
120. Questions and Answers: FDA approves a Risk Evaluation and Mitigation Strategy
(REMS) for Extended-Release and Long-Acting (ER/LA) Opioid Analgesics, U.S. FOOD
DRUG ADMIN., http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm309742.
htm (last updated Mar. 1, 2013).
121. Evans, supra note 109, at 521-22.
122. See Fox, supra note 29, at 59 (describing the ways in which the FDA could use
REMS restrictions if they chose).
123. Id. (explaining that through a REMS restriction, 'the FDA could require that
physicians prescribing these medications meet the requirerments of safe use as defined under
the statute. ).
124. Id. at 59.
125. Id. (explaining that antibiotics should only be used for bacterial infections and not
viral infections).
126. See Fox, supra note 29, at 59-60.
127. See id. at 60.
128. SeeJAMEs ROBERT NIELSEN, HANDBOOK OF FEDERAL DRUG LAw 38 (George
M undorff & Susan H unsberger eds., 2d ed. 1992).
129. Fox, supra note 29, at 60.
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clinically necessary before prescribing it.130 Further, critics may argue that

the REMS render drug lifecycle management more costly and complex. 131
Still, this is a small burden to bear compared to the large public health threat
of antibiotic resistance.
Lastly, while a REMS restriction may adequately address the issue of
antibiotic conservation, it is just one piece of the puzzle.132 The issue of
antibiotic innovation remains unresolved by this solution, necessitating
further action by Congress. Having described the executive branch-s actual
and potential efforts to combat antibiotic resistance, Part III turns to
Congress- role in combating the growth of antibiotic-resistant bacterial
strains.
III. CONGRESS

ROLE IN COMBATTING ANTIBIOTIC-RESISTANT BACTERIAL
STRAINS

The growth of antibiotic-resistant bacteria may be slowed through
congressional action.133 For the past 30 years, Congress has struggled to
establish legislative strategies to reduce the overuse, curb misuse, and
incentivize the development of novel antibiotic drugs.1" For example, as
described in Figure 1 below, several bills have been introduced in Congress
Figure 1. Proposed Antibiotic-Related Legislation Tirreline

130.
use).
131.
132.
problem
133.
134.

See id. at 60 (explaining that REMS restrictions would curtail inappropriate antibiotic
Evans, supra note l09, at 515.
See Fox, supra note 29, at 60 (describing that RE MS is one part of the larger global
associated with inappropriate antibiotic use).
Orrico, supra note 54 at 283-84.
Id. at 277.

https://lawecommons.luc.edu/annals/vol26/iss1/5

16

Hanrahan: COMBATING RESISTANCE: FEDERAL EFFORTS TO REDUCE OVERUSE, CURB MIS

Combating Resistance

2017

83

to address antibiotic resistance with little success. 13 s To adequately address
this public health concern, Congress must act expediently to address both
conservation and innovation in the field of antibiotics.
In 1995, Congress first addressed the issue of antibiotic resistance
with the Congressional Office of Technology Assessment (COTA) and its
Impacts of Antibiotic Resistant Bacteria report 13 6 Then, the
General Accounting Office (GAO) issued another report to Congress
warning about the emergence, spread, and threat of antibiotic resistance in
1999.137 In 2000, the Public Health Threats and Emergencies A ct aimed to
establish an Antimicrobial Resistance Task Force to coordinate federal
programs and provide grants to combat antibiotic resistance. 13 Shortly
after, in 2001, the E nergy and Commerce Committee presented the
Antibiotic Resistance Prevention Act, which aimed to fund antibiotic
resistance awareness and research.139 However, neither of these bills ever
garnered enough support to pass into law. 140
In 2005, Senator] oseph Lieberman (D-CT) introduced the Project
BioShield II A ct 14 1 The bill aimed to boost R &D to countermeasure against
biological, chemical, nuclear, and radiological weapons, in addition to
infectious disease outbreaks. 142 T he bill included a 'wild-card patent term
extension_ in which 'the patent holder for a novel antibiotic or
counterterrorism agent would receive a patent term extension_ of three
months to two years that may 'be applied either to the antibiotic, the
counterterrorism agent, or any other patent held by the patent owner._143
The bill was never acted upon after its initial hearing following pushback
from lobbying groups representing generic pharmaceutical

135. Andrew Geltman, Defusing the Bug Bomb: Legal Strategies to Conbat Antibiotic
Resistant Infections, 18J. HEALTH CARE L.& POL Y 115,117(2015).

136.

See generally U.S.

CONG., OFF. OF TECH. ASSESSMENT,

OTA-H-6298,

IMPACTS OF

ANTIBIOTIC-RESISTANT BACTERIA iii (1995), http://ota.fas.org/reports/9503.pdf (discussing

what was known about antibiotic-resistant bacteria and describing research and development
directed at controlling them).
137. See generally U.S. Gov T ACCOUNTABILITY OFF., GAO-99-132, ANTIMICROBIAL
RESISTANCE: DATA To ASSESS PUBLIC HEALTH THREAT FROM RESISTANT BACTERIA ARE

LIMITED (1999), http://www.gao.gov/assets/230/227221.pdf (discussing what was known
about the public health burden due to antimicrobial resistance and forecasting the potential
future burden).
138. Public Health Threats and Emergencies Act, H.R. 4964, 106th Cong. (2000); Fox,
supra note 29, at 49.
139. Antibiotic Resistance Prevention Act of 2001, H.R. 1771, 107th Cong. (2001); Fox,
supra note 29, at 49.
140. Fox, supra note 29, at 49.
141. Project Bioshield II Act of 2005, 5. 975, 109th Cong. f 301 (2005).
142. Id.; Jessica P. Schulman, Patents and Public Health: The Problems with Using
Patent Law Proposals to Corbat Antibiotic Resistance, 59 DEPAUL L. REV. 221, 231 (2009).
143. Schulman, supra note 142, at 231 -32.
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manufacturers. 14 Many expressed concerns that these measures would
inevitably delay access to affordable medicine. A similar bill, sans wildcard extension, was introduced in 2006 but remained unsuccessful.145
In September 2007, Representatives Matheson (D-UT) and
Ferguson (R-NJ) introduced the Strategies to Address Antinicrobial
Resistance A ct ('STAA RA ct_), 14 6 which ai med to impede antibiotic
resistance by funding data compilation and stewardship programs.147 The
bill received enthusiastic supportfrom the IDSA and other scientific
organizations, but has not been passed despite the multiple re-introductions
of the bill.148 Also in 2007, Senator Bernie Sanders (I-V T) introduced the
Medical Innovation Prize Act. 149 The bill proposed that the pharmaceutical
manufacturer receive a cash reward for developing a medical innovation,
rather than a traditional patent right.1s0 Cash rewards, unlike patent rights,
incentivize the innovation and conservation of antibiotics because
pharmaceutical companies are not required to capitalize on sales during the
drug s patented years. 11 T hus, a cash prize creates an inducement for
antibiotic development that is otherwise missing in the existing
priceAolume landscape of the pharmaceutical industry. Again, this bill did
not gain popularity and Congress failed to pass the bill. 152
Two years later, in 2009, Representative Slaughter (D -NY), the
only microbiologist in Congress, 1s3 reintroduced the Preservation of
Antibiotics for Medical Treatment Act (PA MTA), which was previously
introduced in 2007 and aimed to eliminate the use of subtherapeuti c doses
of antibiotics in livestock feed. 15 4 The bill sought to reduce the use of

144. Id. at 232.
145. Biodefense and Pandemic Vaccine and Drug Development Act of 2006, S. 2564,
109th Cong. (2006); Schulman, supra note 142, at 232 (explaining that the Biodefense and
Pandemic Vaccine and Drug Development Act of 2006 is aimed at strengthening
countermeasures against outbreaks of illness that are deliberate, accidental, and/or natural).
146. Strategies toAddress Antimicrobial Resistance Act; H.R. 3697, 110th Cong. (2007).
147. Fox, supra note 29, at 49.
148. Strategies to Address Antimicrobial Resistance Act, S. 2313, 110th Cong. (2007);
Strategies to Address Antimicrobial Resistance Act H.R. 2400, 111th Cong. (2009); Fox,
supra note 29, at 49-50.
149. Medical Innovation Prize Act of 2007, S. 2210, 110th Cong. (2007).
150. S. 2210 f 2.
151. James Love, Prizes, Not Prices, to StimulateAntibiotic R&D, ScIDEV. NET (Mar. 26,
2008), http://www.scidev.net/global/health/opinion/prizes-not-prices-to-stimulate-antibioticr-d-. html.
152. S chul man, supra note 142, at 233.
153. Helena Bottemiller, Rep. Slaughter Reintroduces PAMTA, Criticizes FDA Strategy
for Tackling Antibiotic Resistance, FOOD SAFETY NEWS (Mar. 15, 2013), http://www.
foodsafetynews.com/201 3/03/rep-slaughter-reintroduces-pamta-criticizes-fdas-strategy-fortackling-antibiotic-resistance/#.WAUG POgrLX Q.
154. Preservation of Antibiotics for Medical Treatment Act of 2009, H.R. 1549, 111th
Cong. (2009); Fox, supra note 29, at 50.
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antibiotics in livestock by amending the FD&C Act to require animal drug
manufacturers to demonstrate that 'no harm to human health will be caused
due to the development of anti microbial resistance attributable to certain
uses of that particular drug. 155 Representative Slaughter re-introduced
PA MTA s6 in 2013 and 2015 which, again, was proven futile.1 7
In 2011, Representative Phil Gingrey, M.D. (R-GA) introduced the
Generating Antibiotics Incentives Now (GAIN) Act.158 The GAIN Act
sought to reform the patent system by granting an additional five years of
market exclusivity for 'qualified infectious disease products. _ 1 9 At last, the
GAIN Act-s provisions were successful and signed into law in] uly 2012 by
President Obama as part of the Food and Drug Administration Safety and
Innovation A ct.1" Only four antibiotics have become available the in U.S.
market with this designation as of Decenber 29, 2014.161 However, critics
such as Kevin Outterson caution that efficacy of this law should not be
overstated, warning that 'qualifying infectious disease product designations
should not be interpreted as evidence of accelerated antibiotic
devel opment. _162
In December 2013, Phil Gingrey (R-GA) and Gene Green (DTX) introduced the Antibiotic D evel opment to Advance Patient Treatment
(A DA PT) Act.163 T he A DA PT Act made it quicker and less expensive for a
pharmaceutical company to place an antibiotic drug on the market'6 by
amending the F D & C Act to create a pathway for the prompt approval of
anti bacterial drugs intended to treat serious or life-threatening diseases and
conditions.165 The ADA PT Act also requires additional labeling, stating:

155.

AM. VETERINARY

MED. Assoc., PRESERVATION

OF ANTIBIOTICS

FOR MEDICAL

TREATMENT ACT (PAMTA) ' H.R.1552(2016), https://www.avma.org/Advocacy/National/
Congress/Documents/IB PAMTA_2016.pdf; Preservation of Antibiotics for Medical
Treatment Act of 2015, H.R. 1552, 114th Cong. f 4(2015).
156. Preservation of Antibiotics for Medical Treatment Act of 2013, H.R. 1150, 113th
Cong. (2013).
157. GovTRACK, H.R. 1150 (11 3th): Preservation of Antibiotics for Medical Treatrment
Act of 2013, https://www.govtrack. us/congress/bi Ils/113/hrl 150 (last visited J an. 27, 2017).
158. Generating Antibiotic Incentives Now Act of 2011, H.R. 2182, 112th Cong. (2011).
159. GAIN: How a New Law Is Stirmulating the Developrrent of Antibiotics, PEW
CHARITABLE

TRUSTS

(Nov. 7, 2013), http://www.pewtrusts.org/en/research-and-analysis/

issue-briefs/201 3/11/07/gain-how-a-new-I aw-is-sti rul ati ng-the-devel oprment-of-anti bi oti cs.
160. Id.
161. Outterson, supra note 64, at 281.
162. Id.
163. Antibiotic Developrment to Advance Patient Treatrrent Act of 2013, H.R. 3742,
113th Cong. (2013).
164. :ADAPT-: A Regulatory Pathway to Develop Antibiotics and Fight Drug Resistant

Infections, PEW

CHARITABLE TRUSTS

(Jan. 29, 2014), http://www.pewtrusts.org/en/research-

and-analysis/q-and-a/201 4/01 /29/adapt-a-regul atory-pathway-to-develop-anti bioti cs-andfight-drug-resistant-infections.
165. Access to Marketplace Insurance Act, H. R. 3742, 114th Cong. (2015).
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'This drug is indicated for use in a limited and specific population of
patients. _166 T he A DA PT Act, which was never passed into law, also sought
to strengthen resistance monitoring by the CDC by ensuring that up-to-date
and cutting-edge data was avai Iable to the government, as well as to
healthcare professionals. 167

Most recently, in December 2014, Senators Orrin Hatch (R-UT)
and Michael Bennet (D-CO) re-introduced legislation to accelerate the
approval of new antibiotics.1" T he Promise for Antibiotics and
Therapeutics for Health (PAT H) A ct sought to establish a new drug
approval pathway in order to encourage development and streamline the
process of antibiotic drugs in the FDA for an 'identifiable, limited patient
population upon determining that the drug treats a serious or lifethreatening condition and addresses an unmet need. 169 In addition, the
PATH Act requires a special designation on antibiotic drug labels to
indicate their intended use in limited, high-risk populations.170 The
legislation takes a creative approach by emphasizing the importance of such
research, particularly veterans who have encountered antibiotic-resistant
bacteria while overseas.171 The legislation received support from IDSA,
which emphasized that, 'the PATHA ct will not only help spur the
development of urgently needed new antibiotics... [it] will also help
ensure these precious new drugs are used appropriately to limit the
development of resistance. 172
As of November 2016, Congress has yet to act upon the PAT H
Act.17 It is too soon to tell, but Congress- track record indicates general
apathy on the issue.174 This apathy, coupled with lobbying challenges by
both the pharmaceutical and agriculture industries, makes the bill s passage
into law seem unli kely. H owever, with the Obama A dmi ni strati on -s recent
push for antibiotic resistance efforts, the time is ripe for change.17 1 Passing

166.
167.
168.
(2014).
169.
MICHAEL

Outterson, supra note 64, at 280.
H.R. 3742 f 2.
Pronise for Antibiotics and Therapeutics for Health Act, S. 2996, 113th Cong.
Bennet, Hatch Reintroduce PATH Act to Streamline Approval of Antibiotics, SEN.
BENNET ( an. 16, 2015), https://www.bennet.senate.gov/?p=release& id=3229.
Id.
Id.
Id.
See Promise for Antibiotics and Therapeutics for Health Act, 5. 185, 114th Cong.

170.
171.
172.
173.
(2015).
174. Fox, supra note 29, at 48, 51.
175. See Press Release, Office of the Press Sec-y, The White House, FACT SHEET:
Obama Administration Releases National Action Plan to Combat Antibiotic-Resistant
Bacteria (Mar. 27, 2015), https://www.whitehouse.gov/the-press-office/2015/03/27/factsheet-obarm-admi ni strati on-releases-national-action-plan-combat-ant (releasing a plan for
federal departments and agencies to combat the rise of antibiotic-resistant bacteria); see
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the PATH Act would be a positive step to incentivize the development of
antibiotics through reducing the burden of the clinical trial process, as well
as to encourage conservation through labeling changes.17 6 Congress would
be wise to act expediently to pass the PATH Act as a first step to addressing
both conservation and innovation in the field of antibiotics. Understanding
Congress- I ni tati ons to granting legislation to curb antibiotic-resistance,
Part IV proposes working creatively within the existing statutory
framework to address both pharmaceutical innovation and antibiotic
conservation in the field of antibiotics through the Orphan Drug Act (ODA)
and CSA.
IV. USING EXISTING LEGISLATION TO PROMOTE
ANTIBIOTIC INNOVATION

As demonstrated above, Congress has tried and failed again to
implement regulations to effectively conserve antibiotic drugs and
incentivize the development of new classes of antibiotic therapies. An
alternative to implementing new law is to work creatively within the
existing statutory framework to address both conservation and innovation in
the field of antibiotics. Regarding innovation, the 0 DA may be used to
encourage pharmaceutical manufacturers to invest in R & D in the field of
antibiotics." When it comes to conservation, the CSA may be creatively
interpreted to monitor the distribution of antibiotics.178
A. The Orphan Drug Act
The ODA was passed in 1983 to encourage research for the
treatment of rare conditions affecting less than 200,000 people in the U nited
States.179 Companies may also apply for an orphan designation without
hitting this benchmark if they can establish that developing a drug for the
condition is otherwise economically disadvantageous because there is 'no
reasonable expectation _ that sales could support development of the drug in
the United States.1 so The ODA is a form of 'federal cost-shari ng for
qualified research projects that also aims to lessen the cost and regulatory
burden of the clinical trial process.181 The ODA encourages pharmaceutical

generally

NATIONAL STRATEGY,

supra note 8 (outlining the goals of the United States

Government to reduce antibiotic resistant bacteria and protect the public from related threats).
176.
See 5. 2996.
177.
See Kesselheim & Outterson, supra note 83, at 139 (explaining that the ODA can
decrease up-front costs of R&D through tax incentives and research grants).
178.
See Geltman, supra note 135, at 123 (conjecturing that scheduling under the CSA
night be qualified because there is evidence that some antibiotic misuse is psychological).
179.
21 U.S.C. f 360ee(b)(2) (2006).
180. Id.
181.
Kesselheim & Outterson, supra note 83, at 139.
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manufacturers by providing federal funding for grants and contracts to
perform clinical trials for orphan products, offering a research tax credit of
fifty percent of clinical testing costs, and guaranteeing a seven year market
exclusivity period from the date of marketing approval.18 2 From 1983 to
2010, over 350 therapies entered the United States market with orphan
designations." While the ODA has been most effective in oncology drugs,
it has been used for products that target infectious diseases as wel l.1
T he 0 DA hel ps address the issue that arises from the pri ce/Vol ume
model of the pharmaceutical industry, which would otherwise avert
pharmaceutical companies from investing in R&D for rare diseases. The
ODA has already incentivized pharmaceutical manufacturers to pursue
antibiotic R&D by decreasing the upfront R&D costs.186 Indeed, the

FDAAA of 2007 financially supported a conference to deternine when
ODA incentives for certain antibiotics developed to treat infectious diseases
due to antibiotic-resistant bacteria. 1 7 T here has since been an increase in
antibiotic therapies with Orphan Drug designation without any significant
change to the law. 1" While the ODA incentivizes innovation, it does not
address the issue of antibiotic conservation.' Thus, the ODA should be
looked at as just one piece of the puzzle, rather than a cure-all to solve
antibiotic resistance. 19o
B. The Controlled Substances Act
The CSA is the federal government-s primary means of controlling
the supply of drugs.191 The statute allows the federal government to control
access and use of certain drugs, and it can even eliminate classes of drugs
182.
183.
184.
185.
ORPHAN

186.

Id. at 140.
Id.
Id. at 141.
See Henry A. Waxman, The History and Development of the Orphan Drug Act, in
DISEASES & ORPHAN DRUGS 135,139-40(1986).
Enrique Seoane-Vazquez et al., Incentives for Orphan Drug Research and

Development in the United States, 3

ORPHANET J. OF RARE DISEASES

1, 5 (Dec. 16, 2008),

https://www.ncbi.nim.nih.gov/pmc/articies/PMC2631478/pdf/1750-1172-3-33.pdf.
187. Food and Drug Adnin. Amendments Act of 2007, Pub. L. No. 110-85f 1112, 121
Stat. 976 (2007).
188. Kesselheim & Outterson, supra note 83, at 140-141 ('In thefirst half of 2008, two
of the sixty-one new orphan drug designations related to antibiotics. For example, one of the
orphan drug designations was granted to Mpex Pharmaceuticals for an IDSA-designated
priority pathogen, specifically for the :[t]reatment of pulmonary infections due to
Pseudormnas aeruginosa and other bacteria in cystic fibrosis patients. _.
189. Id. at 142.
190. See id.
191. Thoms M. Quinn & Gerald T. McLaughlin, The Evolution of Federal Drug Control
Legislation, 22 CATH. U. L. REV. 586, 605 (1973) (explaining that the enactment of the CSA
repealed all prior federal drug legislation and created a comprehensive scheme for drug control
in one statute).
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from the market. 192 One must register with the Drug Enforcement Agency
(DEA) to prescribe or dispense a scheduled drug." A ll scheduled drugs
require the prescriber and dispenser to keep accurate and detailed records of
their transactions. 194 In addition, Schedule I and II drug prescriptions
require each order to be placed on a triplicate, with one copy forwarded to
the DEA.195 The CSA also provides disincentives to physicians for drug
over-prescription in the form of penalties, ranging from a $100,000250,000 fine to up to one year in prison for first-time offenders. 19 6
T he CSA can theoretically incorporate antibiotics as a Schedule V
controlled substance.197 T he Department of Health and Human Services
(H HS) Secretary and the Attorney General (AG) (or the DEA with the
AG -s delegated authority) share drug-scheduling authority.19 When
scheduling a drug, the HHS makes medical judgments 99and scientific
determinations about a specific drug product, and the AG promulgates the
rules relating to the registration and control of the 'efficient execution of his
functions._ 20 Eight factors are considered in determining whether the
scheduling should be authorized: (1) the actual or potential abuse of the
drug; (2) the scientific evidence of its pharmacological effect (3) the state
of current scientific knowledge; (4) the history and current pattern of abuse
of the drug; (5) the scope, duration, and significance of the abuse; (6) the
risks to the public health; (7) the psychic or physiological dependence
liability; and (8) whether the substance is an immediate precursor of a
substance already controlled under this subchapter.201
T he CSA establishes three elements for Schedule V drugs: (1) the
drug has a low potential for abuse relative to the drugs or other substances
in schedule IV; (2) the drug has a currently accepted medical use in
treatment in the United States; and (3) abuse of the drug may lead to limited
192.
193.

21 U.S.C. f 812 (2012).

194.

BRIAN T. YEH, CONG. RESEARCH SERV., RL34635, THE CONTROLLED SUBSTANCES

NIELSEN, supra note

128, at 67.

ACT: REGULATORY REQUIREMENTS

195.
196.

2(2012).

Id. at 97.
BRIAN T.

YEH, CONG. RESEARCH SERV., RL30722, DRUG OFFENSES: MAXIMUM
FINES AND TERMS OF IMPRISONMENT FOR VIOLATIONS OF THE FEDERAL CONTROLLED
SUBSTANCES ACT AND RELATED LAWS 6(2015).

197. Scott B. Markow, Penetrating the Walls of Drug-Resistant Bacteria: A Statutory
Prescription to Conbat Antibiotic Misuse, 87 GEO. L.J. 531, 542 (1998) ('The Attorney
General may be able to schedule antibiotics based on potential for abuse by prescribers and

the risk that they pose to the public health.).
198. Gonzales v. Oregon, 546 U.S. 243, 265 (2006).
199. Id. at 265.
200. Id. at 259.
201. 21 U.S.C. f 811(c)(1)(7) (2015).
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physical dependence or psychological dependence relative to the drugs in
Schedule IV.202 Other Schedule V drugs include anti di arrheal, antitussive,
and analgesic medications. 203 Antibiotic drugs could fall under the purview
of the CSA if the H HS Secretary established scientific findings to
demonstrate that misuse or abuse of antibiotics constitutes a threat to public
health, thereby justifying federal control of the drug and satisfying the first
element of a Schedule V drug under the C SA .2 This would be an
innovative use of the CSA because the purported abuse not only harms the
individual, but the greater concern is one of public health. As noted above,
the CD C reports that up to fifty percent of all anti bi oti cs prescribed are
unnecessary, giving rise to the looming public health threat of antibiotic
resistance.205
To avoid penalties or liability through the over-prescription of
antibiotics, doctors need only do what they are already supposed to do:
prescribe antibiotics when it is medically necessary to do so. 20 6 However,
critics of controlled substance laws suggest that they deter doctors from
providing appropriate medication.207 Such efforts may threaten physician
autonomy by interfering with the practice of medicine and run the risk of a
chilling effect on the appropriate prescription of antibiotics to patients who
actually need them, thereby adversely affecting patient outcomes. 208 Still, in

clinical practice, scheduling a drug does not necessarily lead to limiting
access to patients who need then 2 09 Rather, the system merely adds a
system of checks on the prescribing physician to affirm that the drug is
clinically necessary before prescribing it.2 10 Further, the CSA does not
address the issue of antibiotic innovation; it is just one potential piece in a

&

202. 21 U.S.C. f 812(b)(5) (2012).
203. U.S. DRUG ENFORCEMENT ADMIN., Drug Scheduling, http://www.dea.gov/druginfo/
ds.shtml (last visited Nov. 14, 2016).
204. See 21 U.S.C. f 81 1(c)(6) (2015) (noting that the danger of the drug to the public
health is a factor that should be taken into account when making scheduling decisions).
205. See CTR. FOR DISEASE CONTROL & PREVENTION, Antibiotic Resistance Questions
Answers, http://www.cdc.gov/getsrmrt/community/about/antibiotic-resistance-faqs.html (last
updated Apr. 17, 2015) (noting that the unnecessary overuse drives resistance).
206. Markow, supra note 197, at 542 (discussing how the law places no linits on when a
particular legend drug may be prescribed).
207. SeeThe Supreme Court ' Leading Cases: Gonzales v. Oregon, 120 HARV. L. REV.
361, 365 (2006) (discussing how the CSA was not intended to regulate medical practice and
was meant to prevent drug abuse).
208. See Fox, supra note 29, at 59-60; see also Evans, supra note 109, at 514 (limiting
physician prescription practices may inhibit physicians from prescribing antibiotics to patients
who could benefit from the antibiotics).
209. See Fox, supra note 29, at 59 (discussing a RE MS restriction on antibiotics that are
in need of preservation).
210. See id.
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broader and more comprehensive scheme to effectively combat antibiotic
resistance.2 11
V.A COMPREHENSIVE STATUTORY RESPONSE TO ANTIBIOTIC RESISTANCE

The enormous public health threat of antibiotic resistance requires
more than just 'feel good_ action without any statutory or regulatory teeth.
It necessitates sweeping regulations to reduce the overuse, curb misuse, and
incentivize the development novel antibiotic drugs. Passing new statutory
and regulatory guidelines will take time, coordination, and perseverance.
Until a new regulatory regime surrounding antibiotics is established, it is
essential to work creatively within the existing statutory frameworks to curb
resistance. These efforts should focus on both the conservation of antibiotic
drugs and the innovation of new antibiotic therapies.
In regards to antibiotic innovation, Congress should, first and
foremost, adopt the PAT H Act to establish a new drug approval pathway
within the FDA. 212 The PATH Act would incentivize antibiotic
development by lessening the burden of the time-consuming and expensive
clinical trial process through a new establishing regulatory approval
pathway. Until C ongress acts to pass new legislation, pharmaceutical
companies should take advantage of the existing ODA when developing
novel antibiotics to benefit from the federal funding grants, research tax
credits, and guaranteed market exclusivity period. These measures will
promote the development of novel antibiotic therapies, which have
otherwise proven to be unprofitable in the price/volume driven
pharmaceutical landscape.
On the antibiotic conservation front, the FDA should use its
authority to implement a RE MS restriction for novel antibiotic drugs to
reduce misuse and over-prescribing where antibiotics are not clinically
necessary. Until such time that the FDA acts, the HHS Secretary and the
AG may act to classify certain antibiotics as Schedule V Controlled
Substances under the existing CSA, allowing for DEA enforcement via
penalties, or liability for nisuse or overuse of antibiotics where they are
deemed not clinically necessary. Orchestration amongst these federal actors
will necessarily be complex, but itwill allow for the most detailed and
comprehensive approach to combat the diverse causes of antibiotic
resistance. These combined efforts could provide a robust and multifaceted
federal approach to address antibiotic resistance and protect the public
health.

211.
212.

See id.
Chris Dali, Health Groups Urge Senate to Pass Antibiotics Bill, U. MINN. CTR. FOR
INFECTIOUs DISEASE RES. & POLY (Sept. 6, 2016), http://www.cidrap.umn.edu/news-persp
ective/201 6/09/health-groups-urge-senate-pass-anti bioti cs-bill.
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